|
Nuformix PLC on Wednesday said fresh analysis of lung tissue from patients with idiopathic pulmonary fibrosis and autoimmune-related interstitial lung disease showed ‘positive’ results for its lead asset NXP002, supporting its potential in treating a wider range of fibrotic conditions. The London-based developer of treatments for fibrosis and oncology said the findings stemmed from re-analysed data of a precision-cut lung slice disease model using lung tissue from transplant recipients with IPF and autoimmune ILD. The update follows ongoing talks with potential licensing and development partners. Nuformix said a consistent dose-dependent effect of NXP002 was observed across biomarkers linked to fibrosis, both as a standalone therapy and in combination with standard-of-care treatments. Importantly, the drug also appeared to support tissue repair by maintaining expression of the Col1A1 gene when appropriate, while dampening its overexpression during active fibrosis. ‘The emergence of data supporting additional activity towards Col1A1 overexpression is exciting,’ said Executive Director Dan Gooding. ‘Inhaled approach towards treatment would be highly advantageous in both development and treatment.’ Nuformix said the results strengthen the case for NXP002’s development and differentiation from existing therapies, which may hinder healthy tissue repair. Discussions with potential partners are ongoing, and further updates are expected. Shares in Nuformix were down 6.5% at 0.11 pence in London on Wednesday afternoon. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
